A placebo-controlled blind trial of cyclosporin-A in prevention of corneal graft rejection in rabbits.

AUTOR(ES)

Bell, T A

RESUMO

Cyclosporin-A (CyA) administered to rabbits intramuscularly in a dose of 25 mg/kg/day for 14 days following interlamellar corneal grafting had a significant effect in preventing rejection of the corneal graft (p less than 0.05), and the benefit was maintained. Rejection was attended by an initial mild inflammatory reaction and followed by a protracted intense response involving a variety of cell types, with subsequent loss of epithelium. endothelium and keratocytes, and the development of areas of stromal necrosis. CyA suppressed this rejection response.

Documentos Relacionados

• Corneal graft rejection: a new rabbit model and cyclosporin-A.
• Randomised, double blind, placebo‐controlled trial of selenium supplementation in adult asthma
• Double-blind, crossover, placebo-controlled clinical trial with clobetasol propionate in desquamative gingivitis
• The prevention of anastomotic leakage after total gastrectomy with local decontamination. A prospective, randomized, double-blind, placebo-controlled multicenter trial.
• Effectiveness of tamsulosin in prevention of post-operative urinary retention: a randomized double-blind placebo-controlled study